This edition of HIV Nursing Matters introduces one of the most exciting and highly anticipated antiretroviral (ARV) drugs to enter the HIV treatment space. Dolutegravir (DTG) – a drug with low cost, convenient dosing schedule, high potency, rapid virucidal activity, low toxicity, high genetic barrier to resistance, limited drug-drug interactions, and availability in single-tablet regimen – appears to tick virtually all the boxes of an ideal ARV. However, concerns about teratogenicity emerged just prior to its anticipated entry into the South African formulary in 2018. This delayed its introduction into the South African public healthcare system because of the layer of complexity this imposed on mass rollout of this new ‘wonder drug’. Finally, this drug is poised to make an entry into the SA public health sector, come 2020. This edition of HIV Nursing Matters provides an in-depth overview of all relevant characteristics of DTG by experts in the field. The issue covers the mechanism of action, advantages of its use, role in treatment-naïve and -experienced subjects, risks associated with its use in situations where supporting drugs in the regimen are ineffective (functional monotherapy), side-effects of the drug, common drug interactions, impact on liver and renal function, use in the face of renal and liver dysfunction, and its use in women of child-bearing age and pregnancy. The issue ends with a most pertinent piece on the impact of drug stock-outs, a challenging reality of our fragile healthcare system.